Abstract
Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.
| Original language | Italian |
|---|---|
| Pages (from-to) | 187-193 |
| Number of pages | 7 |
| Journal | Trends in Medicine |
| Volume | 9 |
| Issue number | 4 |
| Publication status | Published - Oct 2009 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)
Cite this
Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule. / Danza, Katia; Petriella, Daniela; Galetta, Domenico; Fistola, Ettore; Pinto, Rosamaria; Pilato, Brunella; Martinucci, Marianna; Bonucci, Massimo; Tommasi, Stefania; Numico, Gianmauro; Silvestris, Nicola.
In: Trends in Medicine, Vol. 9, No. 4, 10.2009, p. 187-193.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule
AU - Danza, Katia
AU - Petriella, Daniela
AU - Galetta, Domenico
AU - Fistola, Ettore
AU - Pinto, Rosamaria
AU - Pilato, Brunella
AU - Martinucci, Marianna
AU - Bonucci, Massimo
AU - Tommasi, Stefania
AU - Numico, Gianmauro
AU - Silvestris, Nicola
PY - 2009/10
Y1 - 2009/10
N2 - Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.
AB - Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.
KW - Anti-EGFR
KW - NSCLC
KW - Pharmacogenetics
KW - Tyrosine-kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=75749132849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75749132849&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:75749132849
VL - 9
SP - 187
EP - 193
JO - Trends in Medicine
JF - Trends in Medicine
SN - 1594-2848
IS - 4
ER -